SonALAsense, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.sonalasense.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM
Phase 1
Terminated
- Conditions
- Recurrent GBM
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- SonALAsense, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05370508
- Locations
- 🇺🇸
Ivy Brain Tumor Center, Phoenix, Arizona, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients With DIPG
Phase 2
Terminated
- Conditions
- Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- SonALAsense, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05123534
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's National / Children's Research Institute, Washington, District of Columbia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
News
No news found